HIV/AIDS Postexposure Prophylaxis
TDF-3TC-d4T most tolerated regimen for nonoccupational postexposure prophylaxis
Published in Hematology Week, August 1st, 2005
"Nonoccupational postexposure prophylaxis (NPEP) for HIV is recommended after high-risk sexual exposure. Because of the high incidence of intolerable side effects observed with protease inhibitor-and zidovudine-based NPEP regimens, our unit changed standard NPEP treatment to 28 days of tenofovir-lamivudine-stavudine (TDF-3TC-d4T)," scientists writing in the journal HIV Medicine report.
"The aim of this study was to compare side effects and numbers of individuals completing NPEP before and after this change. Parameters were compared...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
Source: Hematology Week (2005-08-01)
More Articles from Hematology Week
- Hematopoiesis
B-cell maturation may not be restricted to spleen - Intestinal Tumors
CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors - Trypanosoma Cruzi
Caspase-8 activity required for T cell-mediated immunity against T. cruzi - Tuberculosis
Sample handling variably affects cytokine test results in tuberculosis trials - Adenoma
Heme oxygenase studied, expression in pleomorphic parotid adenomas clarified - Adverse Drug Reaction
Report describes commonly used meds that worsen insulin resistance - More from this issue of Hematology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
